Female Contraceptives in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2032

List of Tables

Abstract

This report covers the 7MM (US, France, Germany, Italy, Spain, UK, Japan) and provides an Excel-based forecast model for the Female Contraceptives market through 2032.

GlobalData estimates 2022 global contraceptives sales to total approximately $7.8 billion across the 7MM covered within this report. The US contributed 74.6% of these sales, generating an estimated $5.8 billion in 2022. Germany was the largest market of the 5EU, with an estimated $642.9 million in sales in 2022 out of the $1.9 billion total 5EU sales. Japan had the least sales of the 7MM, contributing 1.2% of total sales in 2022 and 1.0% in 2023.

Key Highlights

Female contraceptives market will slightly grow during the forecast period, at a CAGR of 0.5%.

Late-stage pipeline therapies are anticipated to drive slight but not significant growth in the contraceptives market.

Hormonal contraceptives with reduced adverse reactions, non-hormonal contraceptives, better compliance and adherence to contraceptives, access to a wide range of contraceptives and awareness of different contraceptive methods are the greatest unmet needs in the contraceptives space.

Scope

Overview of Female Contraceptives
Annualized Female Contraceptives therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2022 to 2032.
Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the Female Contraceptives therapeutics market.
Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for Female Contraceptives. The most promising candidates in late-stage development are profiled.
Analysis of the current and future market competition in the global Female Contraceptive therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to Buy

Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
Develop business strategies by understanding the trends shaping and driving the 7MM Female Contraceptives therapeutics market.
Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the 7MM Female Contraceptives therapeutics market in the future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

About GlobalData
List of Contents

List of Tables

List of Figures

1 Female Contraceptives: Executive Summary

1.1 Contraceptives market will exhibit slight growth between 2022 and 2032.
1.2 Key players will continue their competitive position in the contraceptives market over the forecast period.
1.3 The contraceptives market is still in need of therapeutics with better safety profiles.
1.4 Significant opportunity remains in Japan contraceptives market.
1.5 Limited late-stage pipeline drugs in the contraceptives field
1.6 What do physicians think?

2 Introduction

2.1 Catalyst
2.2 Related reports
2.3 Upcoming reports

3 Disease Overview

3.1 Contraception
3.2 Other indications

4 Current Treatment Options

4.1 Overview

5 Unmet Needs and Opportunity Assessment

5.1 Overview
5.2 Hormonal contraceptives with reduced adverse reactions
5.3 Non-hormonal contraceptives
5.4 Better compliance and adherence to contraceptives
5.5 Access to a wide range of contraceptive methods
5.6 Awareness of different contraceptive methods

6 R&D Strategies

6.1 Overview
- 6.1.1 Development of novel non-hormonal contraceptives
- 6.1.2 Utilization of contraceptives for other disease indications
6.2 Clinical trials design
- 6.2.1 Pearl Index as an efficacy tool
- 6.2.2 Selection of an active comparator

7 Pipeline Assessment

7.1 Overview
7.2 Promising drugs in clinical development

8 Pipeline Valuation Analysis

8.1 Overview
8.2 Competitive assessment

9 Current and Future Players

9.1 Overview
9.2 Deal-making trends

10 Market Outlook

10.1 Global markets
- 10.1.1 Forecast
- 10.1.2 Drivers and barriers - global issues
10.2 US
- 10.2.1 Forecast
- 10.2.2 Key events
- 10.2.3 Drivers and barriers
10.3 5 EU
- 10.3.1 Forecast
- 10.3.2 Key events
- 10.3.3 Drivers and barriers
10.4 Japan
- 10.4.1 Forecast
- 10.4.2 Key events
- 10.4.3 Drivers and barriers

11 Appendix

11.1 Bibliography
11.2 Abbreviations
11.3 Methodology
- 11.3.1 Forecasting methodology
11.4 Primary research - key opinion leaders interviewed for this report.
- 11.4.1 Key opinion leaders
11.5 Primary research - prescriber survey
11.6 About the authors
- 11.6.1 Analyst
- 11.6.2 Therapy area director
- 11.6.3 Vice president of disease intelligence and epidemiology
Contact Us

List of Tables

Table 1: Contraceptives: Key metrics in the 7MM
Table 2: Most common types of contraceptives
Table 3: Top 10 deals by value, 2018-22
Table 4: Contraceptives market - global drivers and barriers, 2022-32
Table 5: Key events impacting sales for contraceptives in the US, 2022-32
Table 6: Contraceptives market - drivers and barriers in the US, 2022-32
Table 7: Key events impacting sales for contraceptives in the 5EU, 2022-32
Table 8:Contraceptives market - drivers and barriers in the 5EU, 2022-32
Table 9: Key Events impacting sales for contraceptives in Japan, 2022-32
Table 10: Contraceptives market - drivers and barriers in Japan, 2022-32
Table 11: High-prescribing physicians (non-KOLs) surveyed, by country

List of Figures

Figure 1: Global sales forecast by country for contraceptives in 2022 and 2032
Figure 2: Analysis of the company portfolio gap in contraceptives during the forecast period
Figure 3: Competitive assessment of the late-stage pipeline agents that GlobalData expects to be licensed as contraceptives during the forecast period
Figure 4: Unmet needs and opportunities in contraception
Figure 5: Overview of the development pipeline in contraceptives
Figure 6: Key late-stage trials for the promising pipeline agents that GlobalData expects be licensed for contraceptives in the 7MM during the forecast period
Figure 7: Competitive assessment of the promising pipeline agents that GlobalData expects to be licensed for contraceptives in the 7MM during the forecast period
Figure 8: Competitive assessment of the pipeline drugs benchmarked against oral contraceptives
Figure 9: Analysis of the company portfolio gap in contraceptives during the forecast period
Figure 10: Global (7MM) sales forecast by country for contraceptives in 2022 and 2032
Figure 11: Sales forecast by class for contraceptives in the US in 2022 and 2032
Figure 12: Sales forecast by class for contraceptives in the 5EU in 2022 and 2032
Figure 13: Sales forecast by class for contraceptives in Japan in 2022 and 2032

Female Contraceptives in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2032

Description

Table of Contents

List of Tables

Abstract

Key Highlights

Scope

Reasons to Buy

Table of Contents

Table of Contents

List of Tables

List of Figures

1 Female Contraceptives: Executive Summary

2 Introduction

3 Disease Overview

4 Current Treatment Options

5 Unmet Needs and Opportunity Assessment

6 R&D Strategies

7 Pipeline Assessment

8 Pipeline Valuation Analysis

9 Current and Future Players

10 Market Outlook

11 Appendix

List of Tables

List of Tables

List of Figures

List of Figures